NCT03603002View on ClinicalTrials.gov

Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer

NACompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 16, 2018

Primary Completion Date

September 1, 2021

Study Completion Date

June 27, 2025

Conditions
Non-small Cell Lung Cancer Stage I
Interventions
DIAGNOSTIC_TEST

Post-SABR Biopsy

Post-SABR Biopsy

Trial Locations (1)

21224

Bayview Medical Center, Baltimore

All Listed Sponsors
lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT03603002 - Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer | Biotech Hunter | Biotech Hunter